Update cookies preferences
About us
India Edition
Subscribe
premium
news briefs
startups
stock markets
free stories
renewables
current affairs
who reads us
corporate
companies
Follow us on
TMC Footer Logo

Categories

Internet
Business
Chaos
Opinion
State of the Unicorns
All stories
News Explainer
Free Reads
Company-wise coverage

Subscription Plans

Individual
Corporate
Student
Teacher/university
Friends of TMC
Gifting

Company

About us
Who Reads Us
Editorial code
On the Record
Download the App
Contact Us
FAQs
Privacy Policy
Grievance Redressal
Terms of service
Fair Usage Policy
©2025 Slowform Holdings Ltd.86-90 Paul Street, London, EC2A 4NE.
TMC Logo
Follow us on

Categories

Internet
Business
Chaos
Opinion
State of the Unicorns
All stories
News Explainer
Free Reads
Company-wise coverage

Subscription Plans

Individual
Corporate
Student
Teacher/university
Friends of TMC
Gifting

Company

About us
Who Reads Us
Editorial code
Contact Us
FAQs
On the Record
Download the App
Grievance Redressal
Terms of service
Fair Usage Policy
Privacy Policy
©2025 Slowform Holdings Ltd.86-90 Paul Street, London, EC2A 4NE.

natco pharma

1 ARTICLES

natco pharma
Business
bookmark
Story image
bookmark

Natco just can’t kick its high-risk, high-gain game plan

CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?

AvatarNeethi Lisa Rojan

03 Oct 2024